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Abstract
The International Cancer Microbiome Consortium (ICMC) is a recently launched collaborative between academics and academic-clinicians 
that aims to promote microbiome research within the field of oncology, establish expert consensus and deliver education for academics and 
clinicians. The inaugural two-day meeting was held at the Royal Society of Medicine (RSM), London, UK, 5–6 September 2017. Microbi-
ome and cancer experts from around the world first delivered a series of talks during an educational day and then sat for a day of roundtable 
discussion to debate key topics in microbiome-cancer research.
Talks delivered during the educational day covered a broad range of microbiome-related topics. The potential role of the microbiome in 
the pathogenesis of colorectal cancer was discussed and debated in detail with experts highlighting the latest data in animal models and 
humans and addressing the question of causation versus association. The impact of the microbiota on other cancers—such as lung and 
urogenital tract—was also discussed. The microbiome represents a novel target for therapeutic manipulation in cancer and a number of 
talks explored how this might be realised through diet, faecal microbiota transplant and chemotherapeutics.
On the second day, experts debated pre-agreed topics with the aim of producing a consensus statement with a focus on the current state 
of our knowledge and key gaps for further development. The panel debated the notion of a ‘healthy’ microbiome and, in turn, the concept 
of dysbiosis in cancer. The mechanisms of microbiota-induced carcinogenesis were discussed in detail and our current conceptual mod-
els were assessed. Experts also considered co-factors in microbiome-induced carcinogenesis to conclude that the tripartite ‘interactome’ 
between genetically vulnerable host, environment and the microbiome is central to our current understanding. To conclude, the roundtable 
discussed how the microbiome may be exploited for therapeutic benefit in cancer and the safety implications of performing such research 
in oncology patients.
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The ICMC was formed in 2017 with the aims of establishing an international expert consensus on the interaction between the human 
microbiome and cancer and its exploitation for therapeutic benefit. To that end, the inaugural ICMC meeting was held at the Royal College 
of Medicine, London, UK on 5–6 September 2017. The two-day meeting comprised a one-day educational event with lectures delivered by 
international experts to a broad-ranging, clinical and non-clinical audience highlighting cutting-edge research on the role of the microbiome 
in benign and malignant disease. On the second day, experts met for a roundtable discussion to develop a consensus statement regard-
ing the role of the microbiome in carcinogenesis, with a focus on the current state of our knowledge and key gaps for further development.
Day one—‘The microbiome in cancer and beyond’ educational event
The educational event was run in conjunction with the Trainees Section of the RSM and saw 16 academics and academic-clinicians from Europe, 
the Americas and Asia deliver a wide range of talks on the clinically relevant aspects of microbiome research. While the focus was on malignant 
disease, talks covered a variety of disciplines, including gynaecology, respiratory medicine, surgery, gastroenterology and pharmaceuticals. The 
day was attended by approximately 100 delegates and the broad appeal of microbiome research was reflected in the varied backgrounds of the 
attendees: clinicians, basic scientists, medical students, PhD students and veterinarians. It is unusual to have speakers of such diverse interna-
tional origins at a relatively small meeting and it afforded an intimate atmosphere in combination with talks by world-leading experts.
The first session focussed on the role of the gut microbiome as an aetiological agent in colorectal cancer, almost certainly the most well-
developed area of microbiome-oncology research. Professor Julian Marchesi (Professor of Digestive Health at Imperial College London, 
UK) and Dr Harpreet Wasan [Gastrointestinal (GI) lead for Medical Oncology at Imperial College Healthcare NHS Trust, UK] set the scene 
with introductory talks on the technical aspects of performing microbiome research—defining key terms (Box 1) and delineating the benefits 
and drawbacks of metagenomics and 16S rRNA gene-based metataxonomics over traditional culture-based techniques—and the current 
paradigms of colorectal carcinogenesis. Professor Christian Jobin (Professor of Medicine, University of Florida College of Medicine, USA) 
built on this by highlighting mechanisms by which commensal GI bacteria, the so-called ‘enemy within’, may promote carcinogenesis, 
including elegant work in gnotobiotic mice demonstrating how the Escherichia coli-derived colibactin virulence factor induces host DNA 
damage and drives tumourigenesis [1, 2]. Professor Rex Gaskins (Professor of Immunobiology, University of Illinois at Urbana-Champaign, 
USA) reinforced this notion in an illuminating lecture describing how hydrogen sulphide, produced by commensal sulphate-reducing bacte-
ria from the metabolism of dietary sulphated amino acids, has genotoxic, pro-inflammatory and pro-carcinogenic effects [3]. There followed 
a lively debate session, chaired by Professor Julian Teare (Professor of Gastroenterology, Imperial College London, UK), titled, ‘The micro-
biome and cancer: driver or passenger?’. Dr David Hughes (Honorary Lecturer, Royal College of Surgeons in Ireland) and Professor Jun Yu 
(Professor in the Department of Medicine and Therapeutics, Chinese University of Hong Kong) used data from a number of human studies 
[4–6] to present strong arguments in favour of the gut microbiome as a driver of human colorectal cancer. Playing devil’s advocate were 
Professors Robert Brown (Chair in Translational Oncology and Head of Division of Cancer, Imperial College London, UK) and Luis Mur 
(Professor and Director of Research of the Biology and Health Theme, Aberystwyth University, Wales, UK) who cautioned that, although 
there is substantial evidence associating the microbiome with various malignancies [7], direct evidence of causation in humans remains to 
be proven and will require carefully designed longitudinal cohort studies. Although the audience (and possibly panel members) were per-
haps somewhat biased, there was a general consensus that the human microbiome almost certainly has a role to play in carcinogenesis, 
though its relative contribution compared to host genetics and other environmental factors is still to be quantified.
The first afternoon session saw an eclectic mix of talks showcasing microbiome research in various disease states. Dr Alexander Swidsinksi 
(Department of Medicine, Charité Universitätsmedizin Berlin, Germany) delivered a thought-provoking talk, supplemented with stunning fluores-
cence in situ hybridisation images (Figure 1a), on the functional anatomy of the human colon as a bioreactor and the key role of the gut mucus 
layer in providing physical separation between luminal microorganisms and colonic mucosa [8]. Professor Daniel Rosenberg (Chair in Cancer 
Biology and Professor of Medicine, University of Connecticut Health Centre, USA) also presented some fantastic pictures (Figure 1b) taken 
from colonoscopies performed in mice in his lecture describing how nutritive components of walnuts can promote the formation of a microbiome 
with antitumour properties in mice [9]. Moving away from the gut microbiome, Professor Hans Verstraelen (Professor of Urogynaecology, Ghent 
University Hospital, Belgium) described the vaginal microbiome and its potential role in cervical cancer [10], while Professor Jeremy Burton 
(Miriam Burnett Chair in Urological Sciences, Lawson Health Research Institute, Canada) presented his novel work on the microbiome of the 
urinary tract (which was thought to be sterile) and early suggestions of a role in urologic malignancies [11]. Professor Burton also highlighted 
the interesting link between the intestinal microbiome and urologic disease—metabolites and xenometabolites produced by the gut microbiome 
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are often renally excreted and so can affect the urinary tract. Lastly, Professor Luis Mur described distinct microbiome changes in the sputum 
from patients with lung cancer and raised the possibility of bacterial biomarkers for lung cancer [7].
Box 1. Key terminology in microbiome research (adapted from Marchesi et al 2015 [21]).
Bacterial cometabolites: Biologically active substances, such as short chain fatty acids and secondary bile acids, produced by 
bacterial metabolism within the host, typically in the colon.
Dysbiosis: Departure from the healthy microbiome state. There is considerable inter-individual variability in human microbiomes 
and therefore dysbiosis is, at best, a relative term.
Microbiome: The functions or genes of a group of microbiota found in a given environment, e.g., the skin, mouth or colon. In 
man, the combination of these site-specific microbiomes comprises the human microbiome.
Microbiota: A term describing the total collection of microorganisms in a defined environment (e.g., the colon). May contain 
bacteria, archaea, fungi or viruses, although, to date, the majority of studies have focussed solely on bacteria.
Metagenome: The collection of all genomes and genes from members of the microbiota in a sample. Determined by shotgun 
sequencing of DNA and mapping of genes to a reference database. This allows potential characterisation of function of the 
microbiota.
Metataxonomics: A process performed using 16S rRNA gene sequencing to characterise all of the microbiota in a sample or 
group of samples. This allows construction of a metataxonomic tree, wherein the relative abundance of individual taxa can be 
quantified.
Metabolome: The complete set of biologically active elements or metabolites in a single strain or cell type.
Metabonome: The complete set of biologically active elements or metabolites in a system or fluid such as serum or faecal 
water.
Pathobiont: Members of the commensal microbiota that have the potential to cause disease.
Pharmacomicrobiomics: The bidirectional interaction between the host microbiota and drugs.
Prebiotics: Dietary components (e.g., non-digestible fibre) that potentiate the growth or activity of the microbiota.
  
(a) (b)
Figure 1. (a) Anatomy of the faecal cylinder. Hybridisation with Bac303 (Bacteroides) Cy3 (yellow fluorescence) probe. 10–100 µm bacteria-free 
mucus layer (white arrow) covers the faecal cylinder. This mucus limits direct contact between the bacteria and the colonic mucosa. Figure 
courtesy of Dr Alexander Swidsinski. (b) Colonoscopy in a mouse demonstrating colorectal tumour. Figure courtesy of Professor Daniel 
Rosenberg.
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The focus of the final session concerned manipulation of the microbiome for clinical benefit and was of particular interest to the clinical 
members of the audience. Mr James Kinross (Senior Lecturer and Consultant Colorectal Surgeon, Imperial College London, UK) delivered 
an insightful lecture on pharmacomicrobiomics—gut microbiota modulation of chemotherapeutic efficacy and toxicity. He proposed the 
TIMER mechanistic framework to explain microbiota-host-chemotherapeutic interactions—Translocation, Immunomodulation, Metabolism, 
Enzymatic degradation and Reduced diversity (Figure 2) [12]. Switching tack, Dr Benjamin Mullish (clinical research fellow, Imperial Col-
lege London, UK) presented a thorough run-down of the evidence behind the use of faecal microbiota transplant in various disease states 
[13]. He raised several interesting issues regarding donor selection, safety, efficacy, legislation and mechanism of action that suggest that, 
while the therapy certainly has much potential, it is not yet the panacea the tabloid press might have one believe. Dietary manipulation 
of the gut microbiome may be an obvious proposition but high-quality studies in humans are notoriously difficult. The dietary swap study, 
presented by Professor Steve O’Keefe (Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, USA), was all 
the more remarkable therefore for being carried out in rural Africa and delivering convincing histologic, metabonomic and meta-taxonomic 
data showing that diet can rapidly shift the microbiota towards a more or less carcinogenic phenotype [14]. Finally, Professor John Alverdy 
(Sara and Harold Lincoln Thompson Professor of Surgery, University of Chicago, USA), challenged the widely held dogma that anastomotic 
leak after GI surgery is largely due to surgical technique. Rather, Professor Alverdy posited via a series of elegant investigations that col-
lagenase-producing bacteria (such as Enterococcus faecalis and Pseudomonas aeruginosa) can cause leak independent of anastomotic 
technique [15, 16]—this will be music to the ears of self-castigating GI surgeons around the world. 
In summary, the educational aspect of the ICMC meeting provided a detailed, yet broad overview on key, contemporary aspects of micro-
biome research with a focus on cancer. It was also a fantastic forum for debate and discussion between the audience and speakers, 
which frequently spilled out into the breaks between sessions. Interviews with many of the speakers are available on the ecancer website 
(http://ecancer.org/conference/1014-microbiome-in-cancer-and-beyond.php), and a selection of talks are available to watch in full on the 
RSM website (https://videos.rsm.ac.uk). The talks demonstrated that microbiome research is currently undergoing significant expansion to 
address new environmental niches and pathologies, making for an exciting, multidisciplinary science. The potential to increase our under-
standing of the pathogenesis of malignancy is considerable, as is the potential for clinical benefit. The ICMC was formed with exactly this 
in mind and convened for its inaugural roundtable discussion the following day.
the tumour microenvironment30. This phenomenon 
was explored by studying melanoma growth in geneti-
cally similar and the same strain of mice from different 
facilities (Jackson Laboratory (JAX) and Taconic Farms 
(TAC)), which differ in the composition of their gut bac-
teria31. Tumours grew more aggressively in TAC mice 
than JAX mice, but differences in tumour growth and 
immune responses were ablated by co-housing. Transfer 
of faecal material from JAX to TAC mice delayed tumour 
growth and enhanced immune responses in the latter; 
corres ponding transfer in the opposite direction had 
no effect on JAX mice. Furthermore, combination of 
JAX microbiota and anti-PD-L1 monoclonal antibody 
improved tumour control more than individual treatment 
with either in isolation. Sequencing of the 16S ribosomal 
RNA gene also demonstrated that Bifidobacterium spp. 
showed the largest increase in relative abundance in 
JAX-microbiota-fed TAC mice, and also exhibited the 
strongest association with antitumour T-cell responses. 
Finally, mice treated with a Bifidobacterium com-
mercial cocktail markedly improved tumour control, 
with induction of tumour-specific T cells and increased 
T cells in the tumour microenvironment31. This effect 
was abrogated by depletion of CD8+ T cells and by 
heat inactivation of bacteria. The absence of bacteria 
in secondary lymphoid organs suggests that systemic 
immunological effects occurred independently of bac-
terial translocation. Instead, the authors concluded that 
Bifidobacterium-derived signals are mediated through 
dendritic cell activation, as they demonstrated using 
genome-wide transcriptional profiling and functional 
in vitro experiments.
CTLA-4-blockade-induced colitis, an unwelcome 
phenomenon resulting from mucosal immune dysregu-
lation, is seen in approximately one-third of patients 
receiving ipilimumab treatment against metastatic 
mela noma7,32. Dubin and co-workers33 have demon-
strated that over-representation of the Bacteroidetes 
phylum correlates with resistance to this particular form 
of colitis in humans, and that a lack of genetic pathways 
involved in polyamine transport and B vitamin synthesis 
is associated with increased risk of this type of colitis. 
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Figure 1 | An overview of the TIMER microbiota–host interactions that 
modulate chemotherapy efficacy and toxicity. Chemotherapeutics can 
exert their influence through multiple pathways, which are outlined here. 
Translocation: cyclophosphamide can cause shortening of the intestinal villi 
and damage to the mucosal barrier, permitting commensal microorganisms 
to cross the intestinal barrier and enter secondary lymphoid organs. 
Immunomodulation: intestinal microbiota facilitate a plethora of 
chemotherapy‑ induced immune and inflammatory responses. For example, 
Lactobacillus and segmented filamentous bacteria mediate the 
accumulation of type 17 T helper (TH17) cell and type 1 T helper (TH1) cell 
responses26. Bifidobacteria also modify tumour‑specific T‑cell induction and 
increase T‑cell numbers in the tumour microenvironment in patients 
treated with anti‑PD‑L1 immunomodulator. Metabolism and enzymatic 
degradation: direct and indirect bacterial modification of pharmaceuticals 
might potentiate desirable effects, abrogate efficacy or liberate toxic 
compounds. The microbiota harbour a large suite of indirect metabolic 
processes (such as reduction, hydrolysis, dehydroxylation, dealkylation, etc.) 
which could be used for drug metabolism. These secondary metabolites are 
secreted into the circulation and excreted by the kidney, which might in 
turn cause toxicity. Gut bacteria possess β-glucuronidases that cleave the 
glucuronide from the inactive metabolite of irinotecan (SN‑38G), releasing 
active metabolite (SN‑38) in the gut causing diarrhoea. Reduced diversity: 
chemotherapy induces changes in the diversity of the mucosal and faecal 
microbiota through altered biliary excretion and secondary metabolism or 
associated antibiotic use and dietary modifications. As a result, pathobionts 
might predominate, leading to deleterious effects such as diarrhoea and 
colitis. PRR, pattern‑recognition receptor; TAMC, tumour‑associated 
myeloid cell; TLR, Toll‑like receptor; Treg cell, regulatory T cell.
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Figure 2. The TIMER framework summarises t e h nisms by which chem therape tics can inter ct with the gut microbiome. Translocation: 
cyclophosphamide can damage the mucosal bar ier, pe mitting translocation of ommensal bacteri . Immunomodulation: intestinal microbiota 
facilitate a plethora of chemotherapy-induced i u e nd inflammatory respons s. For ex mple, Lactobacillus mediates the accumulation 
of T-helper cell responses and bifidobacteria incr ase T-cell numbers in the tum ur micro nvironment in patients treated with anti-PD-L1 
immunomodulator. Metabolism and enzymatic degradation: the microbiota arbour a larg  suit  of met b lic processes (such as reduction, 
hydrolysis, dehydroxylation and dealkylation) whi h c n modify pharmaceuti als t  pot ntiate desirable effects, abrogate efficacy or liberate 
toxic compounds. For example, bacterial β-glucuronidases cleave the glucuronide from the inactive metabolite of irinotecan (SN-38G), releasing 
the active metabolite (SN-38) into the gut and causing diarrhoea. Reduced diversity: chemotherapy can modify the diversity of the intestinal 
microbiota through altered biliary excretion and secondary metabolism or associated antibiotic use and dietary modifications. The resulting 
expansion of pathobionts can lead to deleterious effects such as diarrhoea and colitis. PRR, pattern-recognition receptor; TAMC, tumour-
associated myeloid cell; TLR, toll-like receptor; Treg cell, regulatory T cell. Reproduced from Alexander et al [12] 2017 with kind permission.
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Box 2. Agenda for discussion by the roundtable.
Session One: Output from ICMC
(a)  As a consortium of experts with an interest in the microbiome, what should we aim to achieve and how might we 
collaborate constructively in this regard?
(b)  When considering the ‘microbiome’ as an aetiological agent in cancer, can we create a useful framework that acknowledges 
carcinogenesis induced by pathogens—such as H. pylori and HPV—compared to pathobiont-associated cancer resulting 
from dysbiosis?
Session Two: Molecular mechanisms of microbiome-induced carcinogenesis
(a)  Microorganisms may influence carcinogenesis in a variety of ways. For example, promoting inflammation, impairing 
immunity, genotoxicity and altered metabolism. What are the broad molecular mechanisms by which microorganisms 
may cause cancer—can we classify them?
(b)  The ‘driver/passenger model’ and the ‘alpha-bug hypothesis’ are two conceptual models by which dysbiosis may cause 
colorectal cancer. Are these models generalisable to other cancers or do we need other models? Is there a unifying 
model to describe how dysbiosis may cause cancer in general?
(c)  With respect to dysbiosis and carcinogenesis, have we moved beyond association to causation?
Session Three: Co-factors in microbiome-induced carcinogenesis
(a)  Are there host genetic and/or epigenetic factors which influence the oncogenic potential of the human microbiome?
(b)  How do environmental factors—such as diet, smoking, stress, exercise, drugs and alcohol amongst others—interact with 
the microbiome to promote carcinogenesis?
Session Four: Safe exploitation of the microbiome for therapeutic benefit
(a)  How might the microbiome be exploited for therapeutic benefit in cancer prevention, diagnosis, prognostication and 
treatment?
(b)  How can we research microbiome manipulation in oncology patients? Does this have patient safety implications?
Day two—expert roundtable discussion on the role of the human microbiome in carcinogenesis
In the roundtable discussion, contributors addressed pre-agreed questions regarding the role of the human microbiome in carcinogenesis 
(Box 2). Selected experts delivered short talks to address a specific question and stimulate discussion. Other designated members of the 
roundtable had also considered the question in advance and provided further views before the question was opened to the roundtable for 
debate and formation of an expert consensus opinion. 
Questions were divided into four sessions. Session one concerned the aims, objectives and output of the consortium. Mr Kinross led the 
discussion and defined the ICMC mission statement as, ‘the promotion of excellence in microbiome cancer research’. Principal functions of 
the consortium were agreed as forming and publishing expert consensus on key and contentious issues in microbiome-oncology research; 
providing education to engage with the scientific, clinical and lay communities; establishing collaboration with the formation of research 
networks and sharing of resources; lobbying and promoting cancer-microbiome research to governments, industry and patient groups; and 
raising funding through relationships with funding bodies and industry partners. One specific area of output the consortium was keen to 
deliver considered the conceptual framework we currently use to describe the microbiome as an aetiological agent in cancer. For instance, 
cancer may be caused by infection with so-called ‘pathogens’ (such as human papilloma virus (HPV) or Helicobacter pylori) or may be 
promoted by the community structure of the commensal microbiome (loosely termed dysbiosis, i.e., ‘the enemy within’). There followed 
an interesting debate as the roundtable, led by Professor Verstraelen, questioned the very nature of the ‘healthy’ human microbiome and, 
by extension, the definition of dysbiosis. After all, can we even define ‘health’ in an individual whose future phenotype is unknown and 
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perhaps unknowable? Furthermore, the ‘gut’ microbiome is largely being profiled by studies on the colon and typically by faecal analysis. 
The microbiota of the rest of the GI tract and mucosal-associated microbes in particular is far less studied. Although opinion was divided 
on this fundamental issue, there was some agreement that the ‘healthy’ microbiome might best be described as a concept of ideals and 
dysbiosis as a departure from this ideal. We know that there is significant inter-individual variability with regard to the composition of the 
gut microbiome, and future studies may well need to consider dysbiosis as relative to the individual concerned rather than an absolute.
The second session focussed on the molecular mechanisms of microbiome-induced carcinogenesis. In the initial discussion, Professors 
O’Keefe and Gaskins highlighted the role of bacterial cometabolites, produced by dietary fermentation, as drivers of gut mucosal health 
and disease. The short chain fatty acid butyrate was cited as a prime example as it is the principal energy source for colonocytes and has 
anti-inflammatory, immunomodulatory and anti-neoplastic properties [17]. Hydrogen sulphide was also noted for its pro-inflammatory and 
genotoxic effects (Figure 3) [3]. Notably, the effects of these metabolites need not be confined to the GI tract and could be implicated in 
tumourigenesis at remote sites such as the urogenital tract. Inflammation, subversion of the immune system and toxin-induced genotoxicity 
were other proposed mechanisms. Professor Marchesi instigated discussion regarding how we might incorporate these mechanisms into a 
conceptual model of microbiome-induced carcinogenesis. Existing models of colorectal carcinogenesis propose that ‘keystone-pathogens’, 
‘alpha-bugs’ or ‘drivers’ promote DNA damage and genomic instability by the aforementioned mechanisms, while subsequent tumour-asso-
ciated microenvironmental changes may favour colonisation by ‘passenger’ species which may be innocent bystanders or further contribute 
to cancer progression [18]. Professor Yu pointed out that depletion of ‘protective’ species from the early tumour microenvironment may also 
be important. However, there was general consensus that these models probably over-emphasise the role of the microbiome at the expense 
of the host and we might be better served by considering a tripartite interactome of vulnerable host, environment and microbiome. Profes-
sor Jobin concluded the session, summarising the evidence that the microbiome can cause cancer. There was overwhelming evidence for 
the role of specific pathogens, such as HPV, H. pylori and Hepatitis B virus, but the evidence for the role of the commensal microbiome in 
carcinogenesis was less substantive. Experimental work in cell lines and animal models certainly provide plausible mechanisms but cur-
rent human data, although compelling, are generally associative. The roundtable consensus was that, while the currently available data 
are persuasive, large and international, longitudinal cohort studies are needed to be more confident of causation rather than association.
A recurrent theme throughout the roundtable discussion was the ‘vulnerable host’. This term encapsulated the notion that the host microbi-
ome alone is not able induce carcinogenesis, but rather that there must be host vulnerabilities that can render host–microbiome interactions 
carcinogenic. In the penultimate session, Dr Hughes explored the two-way interaction between the host genome and microbiome. On the one 
hand, a number of studies have demonstrated correlations between a host allele and a specific microbial phenotype, notably involving genes 
with immunoregulatory functions such as pattern recognition receptors and their adapter proteins [19]. On the other hand, the microbiota 
can induce host epigenetic changes (e.g., via histone deacetylase expression and modulation of host micro-RNA expression) and therefore 
modify host gene expression. Environmental factors too can render the host vulnerable to their microbiome. Swidsinski et al [8] explained 
his core hypothesis that colorectal carcinogenesis principally results from a direct contact between the luminal microbiota and the mucosa 
due to loss of the protective mucus barrier layer. He postulated that disruption of the mucus layer (e.g., by smoking or the emulsifying agent 
carboxymethylcellulose, which is found in many Western foodstuffs) may be a common final pathway by which many environmental agents 
interact with the microbiome to induce inflammation and cancer. While acknowledging the importance of the mucus layer, Professor O’Keefe 
proposed that the effect of the Western diet on colon cancer risk was more likely explained by the bacterial co-metabolism—low fibre intake 
compromising short-chain fatty acid (e.g., butyrate) production and high animal protein/fat intake resulting in the formation of toxic nitrog-
enous and sulphur metabolites. Professor O’Keefe pointed out that metabolites would generally penetrate the mucus layer and exert effects 
on the underlying mucosa.
The roundtable finished with a session, chaired by Professor David Cunningham (Consultant oncologist and Director of Clinical Research 
at The Royal Marsden, London, UK), exploring how the microbiome might be safely exploited for therapeutic benefit in the prevention, diag-
nosis and treatment of cancer. Professor Burton elucidated the broad tools at our disposal to manipulate the microbiome, including diet and 
supplements, surgery (e.g., gastric bypass), faecal transplant, antibiotics, bacteriophages and bacteriocins. With respect to diagnosis and 
prognosis, there are efforts to use faecal 16S rRNA gene sequencing as a biomarker for colorectal cancer [6] and the microbiome profile 
can be correlated with the T stage (Alexander et al [12], unpublished data). Dr Jessica Younes (Science Liaison, Winclove Probiotics, The 
Netherlands) gave an industry perspective on the safety concerns of manipulating the microbiome in oncology patients. Pro- and prebiotics 
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certainly hold promise as therapeutic agents in this patient cohort, particularly with regard to the treatment of radiation-/chemotherapy-
induced enteritis/colitis. However, these patients are especially vulnerable given their immunocompromised state and there is concern 
that the use of pro- or prebiotics may represent a hazard, as was seen with the use of probiotics in patients with severe acute pancreatitis 
(PROPATRIA trial [20]). Despite these concerns, the consortium felt that they could be safely trialled with appropriate caveats; probiotic 
strains should be extensively characterised in vitro; effects on the microbiome and metabonome should be explored in healthy, immuno-
competent hosts; and these agents should be treated as drugs and corresponding good clinical practice followed.
This inaugural ICMC meeting represented the first attempt to bring together scientists and academic clinicians from different fields and 
different countries whose common interest is cancer and the microbiome. We delivered our twin aims of highlighting the importance of the 
cancer microbiome in an educational forum and debating key questions in the field. The consortium now aims to publish an expert consen-
sus statement on the role of the microbiome in carcinogenesis and to develop further strategies for achieving our longer term goals with 
respect to delivery of education, forming research collaboratives and leveraging funding.
Despite the substantial support for carcinogenesis 
b i g linked to an ov rall disturbance in microbi l bal-
ance and integration, accumulating evidence suggests a 
predominant role of Fusobacterium spp. in the neoplastic 
process; biopsy material from adenomas and adjacent 
normal mucosa in 19 patients showed 48% positivity 
for Fusobacteriu  in tumour tissue, which was higher 
than in the normal tissue32. Using the ApcMin/+ mouse 
model of intestinal tumorigenesis, Fusobacterium 
ucleatum was shown to increase tumour multiplicity 
and recruit tumour-infiltrating myeloid cells that can 
promote tumour progression32. Other studies have 
shown that F.  ucleatum-high colorectal cancer  tissues 
were inversely associated with the density of CD3+ 
T cells33 and had a strong association with micro satellite 
instability and CpG island methylator phenotype- 
linked cancers34. These examples demonstrate the com-
plex interactions between micro rganisms,  immunity, 
genetic predisposition and colorectal cancer.
Also noteworthy is the evidence for the potential of 
individual microorgan sms to induce colitis and colo rectal 
cancer in experimental animals35. The microorganism 
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Figure 2 | Importance of dietary residues and the colonic microbiota in det rmining col n cancer risk. In health, 
>90% of a normal diet is absorbed in the small intestine and nutrients are distributed to maintain general body health. 
Residues entering the colon are chiefly complex carbohydrates (fibre), but also contain protein residues and primary bile 
acids secreted by the liver in response to fat ingestion. These residues have a critical role in the maintenance of colonic 
health as they determine the composition and metabolic activity of the colonic microbiota which, through fermentation, 
maintain mucosal and colonic health. With a balanced diet, saccharolytic fermentation of carbohydrates is dominant, 
producing short-chain fatty acids, particularly butyrate, which is the preferred energy source for colonocytes and has 
anti-inflammatory and antineoplastic properties through actions shown. With an imbalanced high-fat, high-meat, 
low-fibre diet, the proinflammatory and proneoplastic properties of protein fermentation and bile acid deconjugated 
residues predominate, leading to increased colon cancer risk.
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Figure 3. Interaction between diet and the microbiota results in the production of c -metab lites which can modify colon cancer risk. 
Saccharolytic fermentation of carbohydrates in fibre generates short-chain fatty acids, such as butyrate, which has anti-inflammatory and  
anti-neoplastic properties as indicated. On the ther hand, a high fat/high animal protein diet promotes the formation of secondary bile acids 
and toxic nitrogenous and sulphur metabolites, which are pro-neoplastic. Reproduced from O’Keefe et al [17] 2016 with kind permission.
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